

Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019

<https://marketpublishers.com/r/IA53D72788C8EN.html>

Date: December 2019

Pages: 74

Price: US\$ 3,500.00 (Single User License)

ID: IA53D72788C8EN

Abstracts

Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019

SUMMARY

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Interleukin-2 receptor alpha is a protein that is encoded by the IL2RA gene. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells.

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) pipeline Target constitutes close to 12 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 3 and 5 respectively. Report covers products from therapy areas Immunology, Oncology, Cardiovascular, Dermatology and Metabolic Disorders which include indications Non-Small Cell Lung Cancer, Colorectal Cancer, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Melanoma, Plaque Psoriasis (Psoriasis Vulgaris), Renal Cell Carcinoma, Solid Tumor, Systemic Lupus Erythematosus, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Diabetic Nephropathy, Diffuse Large B-Cell Lymphoma, Gastric Cancer, Inflammation, Kidney Cancer (Renal Cell Cancer), Kidney Transplant Rejection, Lung Cancer, Ovarian Cancer, Pulmonary Arterial Hypertension, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Relapsed Acute Myeloid Leukemia, Skin Cancer, Soft Tissue Sarcoma, Stroke, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Triple-Negative Breast Cancer (TNBC).

The latest report Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019, outlays comprehensive information on the Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)

The report reviews Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) -
Overview

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) -
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) -
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) -
Companies Involved in Therapeutics Development

Alkermes Plc

Anaveon AG

APT Therapeutics Inc

Bristol-Myers Squibb Co

Courier Therapeutics Inc

Mabtech Ltd

Medicenna Therapeutics Corp

Nektar Therapeutics

Philogen SpA

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Drug
Profiles

ALKS-4230 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APT-602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

basiliximab - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
basiliximab biobetter - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-92252 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daclizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daromun - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Antagonize IL2RB for Graft Versus Host Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDNA-209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NARA-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

NKTR-358 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teleukin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Dormant Products

Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Product Development Milestones

Featured News & Press Releases

Nov 10, 2019: Nektar Therapeutics presents data from first-in-human phase 1a study on novel T regulatory cell stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology

Nov 08, 2019: Alkermes announces new data from ALKS 4230 clinical development program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

Nov 04, 2019: Alkermes to present data from ALKS 4230 clinical development program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

Oct 21, 2019: Alkermes announces clinical collaboration with Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230

Oct 07, 2019: Nektar Therapeutics announces initiation of two clinical studies of novel T regulatory cell stimulator NKTR-358 (LY3471851) in patients with psoriasis and atopic dermatitis

Jun 13, 2019: First-in-Human data presented from Phase 1a Study of NKTR-358, a novel t regulatory cell stimullator, at Annual European Congress of Rheumatology

Jun 12, 2019: Alkermes advances ALKS 4230 into monotherapy expansion Phase of ARTISTRY-1 in patients with renal cell carcinoma or melanoma

Jun 11, 2019: Nektar Therapeutics to host webcast conference call with immunology expert for analysts & investors during 2019 European Congress of Rheumatology (EULAR 2019)

Feb 26, 2019: Alkermes initiates clinical study of ALKS 4230 administered subcutaneously in patients with advanced solid tumors

Nov 06, 2018: Alkermes presents new data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting

Sep 11, 2018: Alkermes expands Phase I trial of ALKS 4230 for advanced solid tumours

Jul 18, 2018: Philogen receives orphan drug designation for the treatment of melanoma

May 18, 2018: EMA review of Zinbryta confirms medicine's risks outweigh its benefits

May 08, 2018: Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus

Mar 15, 2018: TGA: Zinbryta (daclizumab) Product withdrawn after overseas reports of inflammatory brain disorders

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Alkermes Plc, H2 2019
Pipeline by Anaveon AG, H2 2019
Pipeline by APT Therapeutics Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Courier Therapeutics Inc, H2 2019
Pipeline by Mabtech Ltd, H2 2019
Pipeline by Medicenna Therapeutics Corp, H2 2019
Pipeline by Nektar Therapeutics, H2 2019
Pipeline by Philogen SpA, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Alkermes Plc

Anaveon AG

APT Therapeutics Inc

Bristol-Myers Squibb Co

Courier Therapeutics Inc

Mabtech Ltd

Medicenna Therapeutics Corp

Nektar Therapeutics

Philogen SpA

I would like to order

Product name: Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/IA53D72788C8EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IA53D72788C8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970